- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02583893
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To test the association between biochemical response and clinical response.
SECONDARY OBJECTIVES:
I. To estimate complete response rate of sirolimus MEC in patients with high risk AML.
II. To estimate progression free survival in this patient population. III. To collect further information on the safety, tolerability, and efficacy of sirolimus in combination with MEC in patients with relapsed or refractory myeloid malignancies.
OUTLINE:
Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus orally (PO) on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride intravenously (IV) over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
After completion of study treatment, patients are followed up every 3 months for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients must have histologic evidence of high risk acute myeloid leukemia defined as one of the following:
Primary refractory non-M3 AML
- Residual leukemia after a minimum of 2 prior courses of chemotherapy (Same or different)
- Evidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia.
- Evidence of leukemia after induction therapy which, in the opinion of the investigator, would be appropriate for reinduction with sirolimus/MEC therapy.
- Relapsed non-M3 AML
- Previously untreated non-M3 AML age >60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBFβ;MYH11] by cytogenetics, FISH, or RT-PCR
- Previously untreated secondary AML (from antecedent hematologic malignancy or following therapy with radiation or chemotherapy for another disease) with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBFβ;MYH11] by cytogenetics, FISH, or RT-PCR
- Subjects must be ≥ 18 years of age.
- Subjects must have an ECOG performance status of 2 or less (see Appendix1).
- Subjects must have a life expectancy of at least 4 weeks.
- Subjects must be able to consume oral medication.
- Subjects must have recovered from the toxic effects of any prior chemotherapy to =< Grade 1 (except alopecia).
Required initial laboratory values:
- Creatinine ≤ 2.0mg/dL
- total or direct bilirubin ≤ 1.5mg/dL; SGPT (ALT) ≤ 3xULN
- negative pregnancy test for women with child-bearing potential.
- Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.
- Subjects must have a left ventricular ejection fraction (LVEF) of ≥ 45%.
Exclusion Criteria:
- Subjects with FAB M3 (t (15; 17) (q22; q21) [PML-RARα]) are not eligible.
Subjects must not be receiving any chemotherapy agents (except Hydroxyurea).
a) Intrathecal methotrexate and cytarabine are permissible.
- Subjects must not be receiving growth factors, except for erythropoietin.
- Subjects with a "currently active" second malignancy, other than non-melanoma skin cancers are not eligible.
- Subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the past 6 months or serious uncontrolled cardiac arrhythmia are not eligible.
Subjects taking the following are not eligible:
- Carbamazepine (e.g., Tegretol)
- Rifabutin (e.g., Mycobutin) or
- Rifampin (e.g., Rifadin)
- Rifapentine (e.g., Priftin)
- St. John's wort
- Clarithromycin (e.g., Biaxin)
- Cyclosporine (e.g. Neoral or Sandimmune)
- Diltiazem (e.g., Cardizem)
- Erythromycin (e.g., Akne-Mycin, Ery-Tab)
- Itraconazole (e.g., Sporanox)
- Ketoconazole (e.g., Nizoral)
- Telithromycin (e.g., Ketek)
- Verapamil (e.g., Calan SR, Isoptin, Verelan)
- Voriconazole (e.g., VFEND)
- Tacrolimus (e.g. Prograf) Subjects taking fluconozole, voriconizole, itraconazole, posaconazole, and ketokonazole within 72 hours of study drug starting are not eligible. Reinstitution of fluconozole, voriconizole, itraconazole, posaconazole, ketokonazole and diltiazem is permissible 72 hours after the last dose of sirolimus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus, MEC chemotherapy
Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery.
Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical response
Time Frame: Baseline to day 4
|
Defined by change in phosphorylated ribosomal protein S6 (pS6) positive blasts, measured as the % reduction in pS6 positive blasts from baseline to day 4. Biochemical response will be described by mean, median, standard deviation, range and coefficient of variation.
The association between biochemical response and clinical response will be tested by Fisher's exact test.
|
Baseline to day 4
|
Clinical response
Time Frame: Day 45
|
Based on hematologic recovery/day 45 marrow assessed according to International Working Group (IWG) criteria.
The association between biochemical response and clinical response will be tested by Fisher's exact test.
|
Day 45
|
Incidence of adverse events
Time Frame: Up to day 45
|
Recorded and graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Worse toxicity grades observed during treatment will be described.
Toxicities will be graded and tabled.
|
Up to day 45
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) (complete response [CR], CR with incomplete platelet recovery [CRp], or partial response)
Time Frame: Day 45
|
Fraction of patients who achieve CR, CRp, or PR will be assessed.
ORR and 95% exact confidence interval will be computed for all patients and for sensitive and resistant subgroups.
|
Day 45
|
Relapse free survival (RFS)
Time Frame: Time from study entry to first documented progression, death, or last contact, assessed up to 2 years
|
RFS will be estimated by the Kaplan-Meier method.
A landmark analysis of RFS by clinical response (CR+CRp, CRi, PR or no response [NR]) will be computed from day 45 marrow assessment.
Median values and 95% confidence intervals will be calculated.
|
Time from study entry to first documented progression, death, or last contact, assessed up to 2 years
|
Overall survival (OS)
Time Frame: Time from study entry to death or last contact, assessed up to 2 years
|
OS will be estimated by the Kaplan-Meier method.
A landmark analysis of RFS by clinical response (CR+CRp, CRi, PR or NR) will be computed from day 45 marrow assessment.
Median values and 95% confidence intervals will be calculated.
|
Time from study entry to death or last contact, assessed up to 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Margaret Kasner, MD, Thomas Jefferson University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Etoposide
- Etoposide phosphate
- Cytarabine
- Mitoxantrone
- Sirolimus
Other Study ID Numbers
- 15D.377
- 2013-087 (Other Identifier: PRC)
- NCI-2015-01507 (Other Identifier: NCI Trial ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Adult Acute Myeloid Leukemia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent... and other conditionsUnited States
-
Alison WalkerCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Approved for marketingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic LeukemiaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
University of Colorado, DenverThe Leukemia and Lymphoma SocietyCompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in RemissionUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid... and other conditionsUnited States
Clinical Trials on Etoposide
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...UnitedHealthcareActive, not recruitingSmall Cell Lung CancerUnited States
-
University Hospital, BonnCompletedEpendymomas | Recurrent Brain Tumors | Supratentorial PNETs | MedulloblastomasGermany
-
Sun Yat-sen UniversityRecruitingSmall Cell Lung CarcinomaChina
-
Guizhou Medical UniversityUnknownSmall-cell Lung CancerChina
-
Third Military Medical UniversityUnknownExtensive-stage Small Cell Lung Cancer
-
Jiangsu HengRui Medicine Co., Ltd.Enrolling by invitation
-
CephalonWithdrawn
-
Qingdao UniversityUnknownProgression Free SurvivalChina
-
Shanghai Henlius BiotechRecruitingExtensive Stage Small Cell Lung CancerUnited States
-
Annick DesjardinsAstraZenecaCompletedGlioblastoma | GliosarcomaUnited States